Oncology On The Go

As part of its OncView video series, CancerNetwork spoke with Reshma L. Mahtani, DO, Sylvester Comprehensive Cancer Center, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting. In the video series, Gadi discussed the following:·      Extended Adjuvant Therapy for HR+ Breast Cancer

·      NCCN Updates to Genomic Testing in HR+ Breast Cancer

·      Genomic Testing for HR+ Breast Cancer: Best Practices

·      Utilization of The Breast Cancer Index for HR+ Breast Cancer

·      Optimizing Treatment Outcomes in HR+ Breast Cancer

 To watch more videos in CancerNetwork’s OncView series, visit cancernetwork.com.

As part of its OncView video series, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD, University of Illinois College of Medicine, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting. In the video series, Gadi discussed the following:·      Adjuvant Vs Extended Adjuvant Therapy in HR+ Breast Cancer

·      Predictive and Prognostic Factors in HR+ Breast Cancer

·      Role of Genomic Testing in HR+ Breast Cancer

·      NCCN Guideline Updates for the Use of Genomic Assays in HR+ Breast Cancer

·      Identifying Patients for Extended Adjuvant Therapy With the Breast Cancer Index in HR+ Breast Cancer

·      Improving the Management of HR+ Breast Cancer: Next Steps

 To watch more videos in CancerNetwork’s OncView series, visit cancernetwork.com.

This episode features an article published in the April issue of the Journal ONCOLOGY titled “Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer.” The lead author of the research, E. David Crawford, MD, a urologic oncologist, and professor of urology at the University of California San Diego, explained their research into prostate cancer disease states. Among other things, Crawford and the research team talked about next-generation imaging, biomarkers, and redefined prostate cancer disease states to introduce transitional disease into that equation.

The response perspective for this article comes from Rana McKay, MD, an associate professor of medicine and urology at the University of California San Diego. McKay provided some of her thoughts on the idea of redefining prostate cancer disease states and really emphasized the need for clinical research to validate treatment options and current practices.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This episode features an article published in the Journal ONCOLOGY titled “Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.”

CancerNetwork spoke with the corresponding author, Jun Gong, a medical oncologist at Cedars-Sinai Medical Center, to discuss the 4 PARP inhibitors that have undergone significant investigation for the treatment of patients with metastatic castrate-resistant prostate cancer. While elaborating on these PARP inhibitors, Gong also discussed the importance and potential value of successfully integrating these agents into prostate cancer practice.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this episode, CancerNetwork sat down for a conversation with David Johnson, chairman and CEO of Enveric Biosciences. Johnson gave a thorough background of the biosciences company, and detailed the endocannabinoid products Enveric is developing to positively impact the quality of life for patients with glioblastoma.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast anywhere podcasts are available.

This episode of the "Oncology Peer Review On-The-Go" podcast centers around an article publishing in the April issue of the Journal ONCOLOGY, titled “Messenger RNA Vaccines-Beckoning of a New Era in Cancer Immunotherapy.” The article touches on the recent development of mRNA vaccines approved to combat COVID-19, and how this development offers optimism for the future of mRNA to treat patients with cancer. The author, Mehmet Sitki Copur, MD, of the University of Nebraska Medical Center, broke down the basics of mRNA, its history, challenges and potential opportunities around this relatively new class of vaccine.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this episode, CancerNetwork examines an article from the March issue of the Journal ONCOLOGY titled “Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer.” The original research article found that treatment refusal among patients with small cell lung cancer was associated with worse survival, and strategies to increase patient acceptance of the recommended treatment need to be studied further. CancerNetwork spoke with one of the authors, KM Monirul Islam, MD, of the Georgia Medical Center, to learn more about this research.

For the response perspective, CancerNetwork spoke with Jennifer Carlisle, MD, an assistant professor of hematology and medical oncology at Winship Cancer Institute of Emory University. Carlisle spoke about small cell lung cancer, how treatment refusal impacts treatment of a patient, and plenty more regarding this original research.

This week, CancerNetwork sat down for a 1-on-1 conversation with former Chief Medical Officer and Executive Vice President of ASCO, Richard Schilsky, MD, to discuss ASCO’s 2021 "Advance of the Year," molecular profiling driving progress in gastrointestinal cancers. 

Schilsky discussed the progress being made in this field and the top research contributing to the momentum in gastrointestinal cancers, while also elaborating on health equity in cancer research, ASCO’s top research priorities moving forward, and more.

He also explained the changes forced on clinical trials due to the coronavirus disease 2019 (COVID-19) pandemic, and how he anticipates trials can leverage these adjustments moving forward in a post-COVID world.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork examined a review article published in the February issue of the Journal ONCOLOGY titled “Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.” The piece highlights the existing literature regarding the prognostic and predictive capabilities of the 21-gene recurrence score in patients with node-positive breast cancer, focusing on current practice patterns and emerging applications from the surrounding literature. For the summary, CancerNetwork spoke with 2 authors of the review, Alison Laws, MD, an associate surgeon at the Brigham and Women’s Hospital and Philip Poorvu, MD, a medical oncologist at the Dana Farber Cancer Institute. Laws and Poorvu provided valuable information on the process, focus and main takeaways of this review. For the article’s response perspective, CancerNetwork spoke with Sara Hurvitz, MD, a professor of medicine at the UCLA Johnson Comprehensive Cancer Center. Hurvitz detailed a number of studies analyzed by the review article, putting into perspective the findings from various pieces of literature. She expanded on the team’s work, and looked toward the future for treating patients with node-positive breast cancer. 
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Justin Gregg, MD, about a study published in Cancer titled “Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort.” Gregg, an assistant professor of urology at The University of Texas MD Anderson Cancer Center and the lead author of the study, explained that the Mediterranean diet was associated with a lower risk of Gleason Grade group progression among men with localized prostate cancer on active surveillance. Larger follow-up studies are still necessary to verify the patient- and cancer-specific effects of adherence to the Mediterranean diet.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.